Recherche
-
Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
(Brain Sciences. vol. 12, n° 2, pp. 183, 2022-01-29)Article de revueLibre accès -
Do isolated cognitive relapses exist? Commentary
(Multiple Sclerosis Journal. vol. 27, n° 10, pp. 1489-1490, 2021-09)Article de revueLibre accès -
Comparison of Simoa™ and Ella™ to assess serum neurofilament-light chain in multiple sclerosis
(Annals of Clinical and Translational Neurology. vol. 8, n° 5, pp. 1141-1150, 2021-05)Article de revueLibre accès -
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification among Natalizumab Users in France
(JAMA Neurology. vol. 77, n° 1, pp. 94-102, 2020-01-01)Article de revueLibre accès -
Determinants of therapeutic lag in multiple sclerosis
(Multiple Sclerosis Journal. vol. 27, n° 12, pp. 1838-1851, 2021-10)Article de revueLibre accès -
Structure-function coupling as a correlate and potential biomarker of cognitive impairment in multiple sclerosis
(Network Neuroscience. vol. 6, n° 2, pp. 339-356, 2022-06-01)Article de revueLibre accès -
Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis
(Frontiers in immunology. vol. 12, 2021-05-04)Article de revueLibre accès -
Differential vulnerability of thalamic nuclei in multiple sclerosis
(Multiple Sclerosis Journal, 2022-08-12)Article de revueLibre accès -
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
(Neurotherapeutics. vol. 19, n° 2, pp. 476-490, 2022-03)Article de revueLibre accès -
MRI characteristics of MOG-Ab associated disease in adults: an update
(2021)Document de travail - Pré-publicationLibre accès